ESMO 2022 | SYNERGY: 1L chemo-immunotherapy with or without the anti-CD73 antibody oleclumab in advanced TNBC

Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, presents results from the SYNERGY (NCT03616886) trial, a randomized Phase II trial of first-line (1L) durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC). The addition of oleclumab to durvalumab with carboplatin/paclitaxel did not increase clinical benefit rate at week 24 in first-line advanced TNBC, however, ongoing translational research aims to better understand the mechanisms of responses to the study combination. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.